500 cancer patients monitored for years after breakthrough cell therapy
NCT ID NCT06785818
First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 26 times
Summary
This study follows 500 people in South Korea who have already received a treatment called tisagenlecleucel for certain blood cancers (like leukemia and lymphoma). The goal is to track long-term side effects, risk of new cancers, and how well the treatment works over time. No new drugs are given—it is an observational registry that collects data from routine medical care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGBundang Gu, Gyeonggi-do, 13620, South Korea
-
Novartis Investigative Site
RECRUITINGSeongnam-si, Gyeonggi-do, 463-712, South Korea
-
Novartis Investigative Site
RECRUITINGGyeonggi-do, Korea, 10408, South Korea
-
Novartis Investigative Site
RECRUITINGIncheon, Korea, 405 760, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, Korea, 02841, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, Korea, 08308, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, Seoul, 03080, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, Seoul, 06351, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, Seoul, 150-713, South Korea
-
Novartis Investigative Site
RECRUITINGBusan, 49201, South Korea
-
Novartis Investigative Site
RECRUITINGJeollanam, 519763, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, 03722, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, 04401, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, 05505, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, 06591, South Korea
-
Novartis Investigative Site
RECRUITINGUlsan, 44033, South Korea
Conditions
Explore the condition pages connected to this study.